XML 12 R1.htm IDEA: XBRL DOCUMENT v3.6.0.2
Document and Entity Information - USD ($)
 12 Months Ended
Sep. 30, 2016
Jan. 06, 2017
Mar. 31, 2016
Document and Entity Information [Abstract]      
Entity Registrant Name American BriVision (Holding) Corp    
Entity Central Index Key 0001173313    
Amendment Flag true    
Amendment Description

Explanatory Note

 

American BriVision (Holding) Corporation (together with its subsidiary, the “Company” sometimes referred to as “we”, “us” or “our”) is filing this amendment (this “Amendment” or “Form 10K/A”) to its Annual Report on Form 10-K for the period ended September 30, 2016, originally filed on January 12, 2017 (the “Original Form 10-K”) to reflect the restatement of its consolidated financial statements for the year ended September 30, 2016 and related disclosures described below. The restatement of the Original Form 10-K reflected in this Amendment corrects errors principally related to accrual of $6,500,000 of payable and related expense as set forth in the Collaborative Agreement dated December 29, 2015 (“Collaborative Agreement”), as amended, with BioLite, Inc (“Biolite”) in the consolidated financial statements, and revises the disclosure of related parties transactions and commitments and contingencies. Concurrently with the filing of this Amendment, we are also filing amendments to our Quarterly Reports on Form 10-Q for the periods ended March 31, 2016 and June 30, 2016 to reflect the restatement of our consolidated financial statements which reflects the correction of the same type of error with respect to such periods.

 

No other sections were affected, but for the convenience of the reader, this report on Form 10-K/A restates in its entirety, as amended, our Original Form 10-K. This report on Form 10- K/A is presented as of the filing date of the Original Form 10-K and does not reflect events occurring subsequent to the date of the Original Form 10-K.

 

Background of Restatement

 

We noted that there was a delay of accrual for the two payments in total of $10,000,000 as set forth in the Collaborative Agreement : 1) 3.5% of total payment related to the upfront payment shall be made upon the execution of the Collaborative Agreement; and 2) 6.5% of the total payment shall be made upon the first IND submission (which was submitted in March 2016). The Company restated the consolidated financial statements in order to record the related liability and expense in the correct period, as well as providing necessary revision for the footnotes of related parties transactions and commitments and contingencies to reflect a more accurate disclosure.

Items Amended by this Amendment

This Amendment reflects the results of the work described above and includes the restatement of our consolidated financial statements for the year ended September 30, 2016. For the convenience of the reader, this Amendment sets forth the Original Form 10-K, as modified and superseded where necessary to reflect the restatement and other related adjustments, internal control matters, and as otherwise specifically indicated. Specifically, the following items included in the Original Form 10-K are amended by this Amendment:

 

-   Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

-   Part II, Item 8, Financial Statements and Supplementary Data

 

-   Part III, Item 11, Executive Compensation

 

-   Part III, Item 13, Certain Relationships and Related Transactions, and Director Independence

 

-   Part IV, Item 15, Exhibits, Financial Statement Schedules

    
Current Fiscal Year End Date --09-30    
Document Type 10-K    
Document Period End Date Sep. 30, 2016    
Document Fiscal Year Focus 2016    
Document Fiscal Period Focus FY    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status No    
Entity Filer Category Smaller Reporting Company    
Entity Public Float     $ 35,193,896.2
Entity Common Stock, Shares Outstanding   210,821,647